… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters …
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting
… ProQR Announces Results for the First Quarter of 2018 Key … RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s scientific advisory board. LEIDEN, the Netherlands, … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Recently, we entered our first corporate partnership …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… ProQR to Present at Two Investor Conferences in September … at 9:10am ET, Daniel de Boer, Chief Executive Officer of ProQR, will present at the Cantor Fitzgerald Global … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and …
… ProQR Announces Second Quarter 2022 Operating and Financial … CNS therapeutic areas, which have strong alignment with ProQR’s oligonucleotide delivery approaches. The Company will … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …